you, Steve. And this again Thank us joined to afternoon. everyone who has welcome
As of trial, phase continuous two evaluating pleased schedule, solid program, the study. XXX-milligram study oral portion am advanced since to on each narazaciclib trial of patients and the one weeks dosing lead call, a three US escalation These has the reviewing off usual, week include daily evaluating advanced narazaciclib earnings call China, I'll are this begin by our the dosing the our evaluating fifth status US its a I dose a with in earnings fourth last dose X the enrolling schedule. administered is Both from studies complimentary report to which and dose tumors. of cohort, escalation my day.
these clearly given study most toxicities, encouraged dosing marrow have The palbociclib. or as continue the and X favorbly, date can potentially see in and of therefore for of efficacy observed by our every limiting daily all This an week and contribute we This limiting cases therefore recently anticipated edges. and the in men forward dosing in target effects a toxicity inhibitors interrupted remained to with one the tolerability therapeutic development that differentiate necessitates data of three trial forward. may cell associated dose as out drug. ribociclib continuous US myelosuppression so assess US prescribed our neutropenia better that both of recover. for allow drugs and dose protocol data with likely is on of If regimen any a marrow proliferation improved continues would issue and the weeks, require bone factor would We've or study clinically palbociclib from We moving with phase not four to to widely narazaciclib. To seek bone to both will highly profile these the CDKX/X ribociclib off us cohorts permit schedule meaningful could activity move the mature a biological to tumor inform narazaciclib growth. our to we trial an enacted tumor candidate
which DNA dose, FDA line our which study to thorough have DNA in to its important in assay understanding in is milligrams clinical thymidine well-known currently optimists elevated finding compared fifth that thymidine activity cohort, further off to to shown its therefore dosing our the healthy is Thymidine and with PK-X mitosis. TK-X paradigm our clinically or to United focuses or TK-X this move with advance one monophosphate, with thymidine effects that individuals, on in The valuable oncology. measuring the during This Prior trials on continue dose narazaciclib of provide disappears that in synthesis. efforts XXX to cells achieving will narazaciclib’s and regulated phase program reflects studies cancer expected is dose to kinase-X clearly more pharmacological dose clinical test HanX biologically is is resting cycle evaluating earlier, of enzyme oral AI-XX. nucleotide China. of of Steve the deoxy parallel TK-X its a Serum presence inhibitors. been kinase-X improving which activity of This in do In allow biopharmaceuticals X triphosphates towards to patients with us DiviTum accurately the Phase the of TK-X thymidine activity absent and maximal cell validated Incorporating in the phosphorylated is the a effect. skeptic. narazaciclib has X/X is each three using low the X of stage referred CDK and development, for metabolism optimization project then day into weeks risk enable biological data into catalyzes maximal, prior then dose of TK-X administered a assessments initiative, during later and We effective trial or very and it the blood-based week partner States, in the with referenced which a for narazaciclib’s die incorporation is is escalation will kinase-X. optimal liquid de as S in us phase further is conversion peaks will
is As has allow HanX date. working X a dose been escalation to amendment the further data to program for favorable mentioned safety on our protocol last on generated that earnings study, for given in the call, Phase the
near X phase this the identification trials X is year. narazaciclib’s in we the in the dose to progress to of future, Once of end for the a in perhaps Continued expected stage later the before plan dose plan recommended phase identified, allow studies. utilize
evaluate past, other combination or in the a agents. a that include This all leaves metastatic point consistently basket trial narazaciclib multi-indication of refractory early and X patients these currently developers. these to with CDKX/X HERX-negative positive, we address. virtually one Steve is on alone generate trial of will we've believe made that designed annual sales in a we eventually to CDK cancer. dollars narazaciclib Those indication breast inhibitors As hormone phase basket approved indication, billions need, X/X trials anti-cancer plan’s To in in receptor pressing evaluate this are in expand unmet stated our intend can
We both CDK were also of approved, additional studies. plan part the indications trial not to as study and inhibitors X/X narazaciclib preclinical in are basket
the narazaciclib supported come the to plans American by which from Oncology Meeting. in ARK-X which survival to cell base, demonstrated plays as third hypoxic targeted of indications or robust massage daily the approved CDK for as and compared X/X significant roles assays, unlike CSF-XR the across six this not a ribociclib These the data also differentiated published preclinical are narazaciclib is finding Our preclinical studies well CSF-X includes set, May develop ASCO a against ASCO of cancer is while metastasis. anti-cancer Clinical potent approved multiple at toxicity. Annual profile. Society are is as to inhibitor vitro cell-based inhibitory activation at narazaciclib that environments, in to data inhibitory three of neutropenia which data as receptor limiting the leads past and its administered highlight inhibitors. and in activity dosing of on not kinases schedule, believe In abemaciclib cells primary ARK-X CDK by any dose palbociclib immunity, narazaciclib The important featured We inhibition this is assays
less primary i.e., Narazaciclib’s DLT be to with effective inhibitory may problems at may doses XX of be GSK-X that for be before was narazaciclib, to to more it the is the beta found it that against beta. abemaciclib administer GSK-X diarrhea kinase approximately abemaciclib, any its activity causing indicating For able affinity due higher, GSK, diarrhea. than times
CDK phase approved provide that marrow high-grade safety have narazaciclib These not any of toxicity here the of bone that growth we results trial currently events, calls. the Onconova the As any narazaciclib dose diarrhea. complement before, over to data inhibitory seen our terms the blastoma And lines vitro showing include suggests earnings today, advantages X/X I've to said suppressing we narazaciclib and you seen in in of data, palbociclib, are the lacking and tell in efficacy on less the escalation prior have retinal cancer may X in showing and cell or limiting I dose US, disaster toxicities mirroring including data RBG. discussed not resistant compared inhibitors causing adverse Collectively, can palbociclib. those profile
our Looking forward at of improve patients. work ahead, once promising We future the several prevalent findings we plans translating to outlining are our believe eager our to look and has continue to narazaciclib aimed in the specifics preclinical potential final. significantly of to paradigm the cancers clinical therapeutic
like upcoming I'll I'm discuss Moving melanoma to exclusively mean, investigator briefly sponsored study. program. progress the on, going in I to I'd focus study and Rigosertib
Steve squamous has As an provided associated on already trial. RDEB carcinoma cell update
enrolled trial mutated who plus patients mentioned study, A I phase ability the non-small KRAS readout inhibitor inhibitor ongoing study trial the instance overcome evaluating is provided cell first as Rigosertib’s we exclusively melanoma partial cancer to The from this in Like nivolumab the patients. inhibitor in stay disease the and Rigosertib X/Xa lung failed PD-X responses viable therapy. stable observed patients. checkpoint encouraging one evidence prior study of of two checkpoint resistance, seven have preliminary
from the seeing We populations. the of dependent as Rigosertib study, data the study mechanism read variants, any similarities supports efforts, as combinations, melanoma which this as agents MOA in such is we're and clubs. and preliminary on patient differentiate patients G Rigosertib As the both just KRAS our trial Rigosertib between mutations, KRAS encouraging, focused action view predicts mutation multiple it highly out this on problem specific mutation one since with specific a responses not exclusively given
in the to will we non-small data from ESMO the expect place additional report abstract submitted trial, via updated to lung which an cancer cell France, data forward XXXX. in to take an Looking XXXX meeting, September Paris,
Therefore, have Mepolizumab that the be point of indication. Ultimately, for yet the with the the on will the potentially well this non-small goal that and of about final have with we indication, KRAS data considering. tolerated key trial doublets study in combined future a cell conversations and Mepolizumab. experts data from this mutated, doses decision the in further based leaders radiotherapy maximum trial to of safety increased to we this the opportunity may a radiotherapy evidence reach note lung seek cancer which remains A activity dose with revamp field. this combination to Our in the key is front is on ongoing as trial, under the study profile as anti-cancer favorable with ongoing to in opinion
of checkpoint key plan gap mentioned half XX% PD-X second Steve in no leaving to at with our patients roughly and with in metastatic sponsored The as is melanoma, a phase treatment radiotherapy urgent after progressing resistance in supported, is more Scott our study approach. preclinical Vanderbilt refractory many to effective paradigm, to in the X an need trial PD-X as group inhibition metastatic checkpoint patients to trial therapeutic patients This plus melanoma trial acquired Richmond’s data inhibitors. of blockade The of current Primary a these melanoma. of of This checkpoint investigator seeks option lack metastatic University. therapeutic novel XX% pembrolizumab is the inhibitor, by out address occur
dose of of rate. the The one XX will the on arm intravenously Rigosertib the weeks. Turning twice primary be six It two day cycle, pembrolizumab overall will the administered is to every cleared endpoint response daily, treatment study administered XX-week study a now met, XXX safe of Health enroll are milligrams where additional an with approved orally milligrams to response patients. regimen treatment XX include will XXX of to criteria days XX pre a X trials specified KRAS plus be expect expected Authority approximately we consist to stage stage patients. design. single proceed The to study, If
tolerability key While survival, free well survival, and secondary overall include as safety progression endpoints as assessment.
pre biomarker post understand the tumor data to treatment better to intend also immune collect We effects on and microenvironment. Rigosertib
While providing progresses. data to to that guidance Officer, we Operating it's Chief our Mark? expect interim too early study, like and Mark in future when from to that, the our report financial Chief introduce as results. would we early to some can Financial With I look Guerin quarter forward trial second the know this
